Plasma exchange in France: Epidemiology 2001

Transfusion and Apheresis Science

Volumn 29, Issue 2, 2003, Pages 153-157

  Korach, J M ^a   Petitpas, D ^a   Paris, B ^a   Bourgeade, F ^a   Passerat, V ^a   Berger, Ph ^a   Chillet, P ^a  

^a General Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; PLASMA SUBSTITUTE; SERUM ALBUMIN;

ALLERGIC REACTION; ARTICLE; ENDOCRINE DISEASE; EPIDEMIOLOGICAL DATA; FAMILIAL HYPERCHOLESTEROLEMIA; FEVER; FRANCE; GUILLAIN BARRE SYNDROME; HEMATOLOGIC DISEASE; HUMAN; IMMUNOTHERAPY; KIDNEY DISEASE; MACROMOLECULE; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; PATIENT INFORMATION; PLASMAPHERESIS; REGISTER; SHIVERING; TREATMENT INDICATION; VASCULAR DISEASE;

EID: 0042163076     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00120-4     Document Type: Article

References (11)

1. Raphaël J.C., Chevret S., Jars-Guincestre M.C., Chastang C., Gajdos P. Immunoglobulines ou echanges plasmatiques? Syndrome de Guillain-Barré: indications respectives des échanges plasmatiques et des immunoglobulines. Ann. Med. Interne. (Paris). 144(8):1993;526-531.
2. Raphaël J.C., Annane D., Chevret S., Chillet P., Gajdos P. Indications respectives des échanges plasmatiques et de fortes doses d'immunoglobulines dans les polyradiculonévrites et la myasthénie. Presse. Med. 25(31):1996;1516-1522.
3. Gajdos P., Chevret S., Clair B., Tranchant C., Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglo. Ann. Neurol. 41(6):1997;789-796.
4. Gajdos P., Chevret S., Clair B., Tranchant C., Chastang C. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann. NY Acad. Sci. 841(May):1998;720-726.
5. Guillevin L., Cevallos R., Durand-Gasselin B., Lhote F., Jarrousse B., Callard P. Treatment of glomerulonephritis inmicroscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchange. Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann. Med. Interne. (Paris). 148(3):1997;198-204.
6. Clark W.F.et al. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. J. Clin. Apheresis. 6(1):1991;40-47.
7. Wallace D.J., Goldfinger D., Pepkowitz S.H., Fichman M., Metzger A.L., Schroeder J.O.et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J. Clin. Apheresis. 13(4):1998;163-166.
8. Cittanova M.L., Leblanc I., Legendre C., Mouquet C., Riou B., Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet. 348(9042):1996;1620-1622.
9. Boldt J. Hydroxyethylstarch as a risk factor for acute renal failure: is a change of clinical practice indicated? Drug Saf. 25(12):2002;837-846.
10. Sefrin P., Rauch S., Zieglmeyer C. Changes in blood coagulation in treatment with hydroxyethylstarch. Anesthesiol. Reanim. 23(6):1998;149-156.
11. Korach J.-M.et al. Role of replacement fluids in the immediate complications of plasma exchange. Intens. Care Med. 24(5):1998;452-458.